Theralase Technologies announced their lead anti-cancer drug has shown effectiveness in the destruction of a human cervical carcinoma cell line.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced their lead anti-cancer drug has shown effectiveness in the destruction of a human cervical carcinoma cell line.
As quoted in the press release:
Cervical cancer was once one of the most common causes of cancer death for American women, but over the last 40 years, the cervical cancer death rate has gone down by more than 50%, due to the increased use of the Pap test.
In research conducted by Pavel Kaspler, Ph.D., Research Scientist, Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, it has been demonstrated that cervical cancer cells (ME180) were up to 96% destroyed, at an extremely low dose of TLD-1433 (0.1 micromolar), when activated by green laser light (530 nm, 90 J/cm2)
The dark toxicity (TLD-1433, but no laser light applied) was virtually negligible, supporting a high safety margin in the destruction of cervical cancer cells.